Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.

@article{Coniff1995MulticenterPT,
  title={Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.},
  author={R F Coniff and Joel A. Shapiro and Timothy B Seaton and George A. Bray},
  journal={The American journal of medicine},
  year={1995},
  volume={98 5},
  pages={443-51}
}
BACKGROUND Acarbose delays release of glucose from complex carbohydrates and disaccharides by inhibiting intestinal alpha-glucosidases, thereby attenuating postprandial increments in blood glucose and insulin. This multicenter, double-blind, placebo-controlled study compared the efficacy and safety of diet alone, acarbose, tolbutamide, and acarbose-plus-tolbutamide in non-insulin-dependent diabetes mellitus (NIDDM) patients. PATIENTS AND METHODS A total of 290 patients with NIDDM and fasting… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

Similar Papers

Loading similar papers…